Related content

Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome

By Wu Jie   Zhu Yiqing   Jiang Yunfei   Cao Yaoping  

Gynecological Endocrinology, Vol. 24, Iss. 7, 2008-01 ,pp. : 392-398

Informa Healthcare

Access to resources Recommend Favorite

Thiazolidinediones for the Therapeutic Management of Polycystic Ovary Syndrome: Impact on Metabolic and Reproductive Abnormalities

By Elkind-Hirsch Karen E.  

Treatments in Endocrinology, Vol. 5, Iss. 3, 2006-01 ,pp. : 171-187

Adis International

Access to resources Recommend Favorite

Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial

By Fux Otta CarolinaFux   Wior Myriam   Iraci Gabriel S.   Kaplan Raquel   Torres Diana   Gaido María Isabel   Wyse Eduardo P.  

Gynecological Endocrinology, Vol. 26, Iss. 3, 2010-03 ,pp. : 173-178

Informa Healthcare

Access to resources Recommend Favorite

Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome

By Santana L Ferreira   Sá MF Silva de   Ferriani RA   Moura MD de   Foss MC   Reis RM dos  

Gynecological Endocrinology, Vol. 19, Iss. 2, 2004-08 ,pp. : 88-96

Informa Healthcare

Access to resources Recommend Favorite

Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy

By Berker B   Emral R   Demirel C   Corapcioglu D   Unlu C   Kose K  

Gynecological Endocrinology, Vol. 19, Iss. 3, 2004-09 ,pp. : 125-133

Informa Healthcare

Access to resources Recommend Favorite